NKTR-118 + NKTR-118 + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Opioid-Induced Constipation (OIC)
Conditions
Opioid-Induced Constipation (OIC)
Trial Timeline
Jul 1, 2011 → Sep 1, 2012
NCT ID
NCT01395524About NKTR-118 + NKTR-118 + Placebo
NKTR-118 + NKTR-118 + Placebo is a phase 3 stage product being developed by AstraZeneca for Opioid-Induced Constipation (OIC). The current trial status is completed. This product is registered under clinical trial identifier NCT01395524. Target conditions include Opioid-Induced Constipation (OIC).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01395524 | Phase 3 | Completed |
| NCT01384292 | Phase 3 | Terminated |
| NCT01309841 | Phase 3 | Completed |
| NCT01323790 | Phase 3 | Completed |
Competing Products
20 competing products in Opioid-Induced Constipation (OIC)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Naldemedine + Placebo | Shionogi | Phase 3 | 77 |
| Naldemedine + Placebo | Shionogi | Approved | 85 |
| Naldemedine | Shionogi | Phase 1/2 | 41 |
| Naldemedine + Placebo | Shionogi | Phase 3 | 77 |
| Placebo + Naldemedine | Shionogi | Phase 2 | 52 |
| Naldemedine + Placebo | Shionogi | Phase 3 | 77 |
| Naloxegol | Kyowa Kirin | Pre-clinical | 23 |
| NKTR-118 + NKTR-118 + Placebo | AstraZeneca | Phase 3 | 77 |
| NKTR-118 + Usual care | AstraZeneca | Phase 3 | 77 |
| NKTR-118 + NKTR-118 + Placebo | AstraZeneca | Phase 3 | 77 |
| Naloxegol + Placebo Oral Capsule | AstraZeneca | Phase 2 | 52 |
| NKTR-118 + NKTR-118 + Placebo | AstraZeneca | Phase 3 | 77 |
| CB-5945 + Placebo | Merck | Phase 3 | 77 |
| CB-5945 + Placebo | Merck | Phase 3 | 77 |
| CB-5945 + Placebo | Merck | Phase 3 | 77 |
| CB-5945 + Placebo | Merck | Phase 3 | 77 |
| Tegaserod | Novartis | Phase 3 | 77 |
| Tegaserod | Novartis | Phase 3 | 77 |
| Methylnaltrexone bromide + Placebo | Pfizer | Phase 2 | 51 |
| ALKS 37 + Placebo | Alkermes | Phase 2 | 49 |